In addition, deficiency of FYB1 can enhance the cytotoxicity of CD8+ CTL and inhibit the expression of PD-1 in CD8+ effector T cells, thus significantly inhibiting tumor growth and enhancing antitumor immunity [15]. Here, CD8A is linked to neoplasm.